Therapy Areas: Autoimmune
Parthenon Therapeutics, ImaginAb Ink License and Supply Agreement to Advance New Class of Anti-Cancer Therapies' Clinical Development Program
11 November 2022 - - US-based precision oncology company Parthenon Therapeutics and biotechnology company ImaginAb Inc., developing 89Zr crefmirlimab berdoxam (CD8 ImmunoPET) imaging agent and next generation radiopharmaceutical therapies products, have entered into a multi-year, non-exclusive license and supply agreement, the companies said.

Under the agreement terms, Parthenon will use ImaginAb's CD8 ImmunoPET imaging technology in its Phase 1 trial evaluating its lead compound, PRTH-101, which is expected to begin in 2023.

Hot tumors are characterized by the presence of CD8+ T cells that are able to infiltrate the tumor parenchyma.

These tumors often respond to immune checkpoint inhibitors, unlike cold tumors which have few to no CD8+ T cells.

In contrast to both hot and cold tumors, immune excluded tumors have CD8+ T cells in the tumor bed, but these cells are relegated to the tumor stroma by collagen and/or other barriers, thereby preventing them from interacting with tumor cells to perpetuate an anti-tumor response.

PRTH-101 targets the collagen barrier of immune excluded tumors, thereby enabling CD8+ T cells to interact with and kill tumor cells.

Immune-excluded tumors can represent up to 75% of a TME phenotype across different tumor types highlighting the potential for identifying therapeutics that can help many patients.

Under the terms of the agreement, ImaginAb will supply clinical doses of its investigational CD8 ImmunoPET technology to Parthenon Therapeutics for use in the clinical development of PRTH-101 at clinical trial sites across the United States.

Initially, Parthenon Therapeutics will investigate CD8 status in a Phase I dose escalation clinical trial of PRTH-101, both in monotherapy and in combination with anti-PD(L)1 therapy.

The trial is expected to initiate in 2023, with the ability to add dose expansion cohorts at a later date to explore additional rational combination opportunities and tumor types.

ImaginAb will receive payments for providing dose manufacturing and ongoing technical, clinical and regulatory support to enable the successful implementation of its CD8 ImmunoPET technology into Parthenon Therapeutics' clinical trials.

ImaginAb is actively investing in the clinical and global supply chain development of CD8 ImmunoPET agent to provide simple turnkey access to its novel technology for use in clinical research and development.

By collaborating with leading biotech companies, ImaginAb is making progress towards the company's goal of being a key partner in the development of new immunotherapies across multiple cancer types and geographies.

Parthenon Therapeutics is inventing a novel class of anti-cancer therapies that reprogram the tumor microenvironment.

The interplay between cancer cells and their surrounding microenvironment is relevant in drug development as many cancers use the TME to build barriers that shield immune system attack.

One approach, PRTH-101, breaks these barriers to overcome recalcitrant cancers. Based on rigorous, ground breaking research, we are designing a portfolio of drug candidates to treat the right patients at the right time.

ImaginAb is a clinical stage, revenue-generating global biotechnology company developing the next generation of imaging agents and radiopharmaceutical therapy products through its proprietary minibody and cys-diabody platforms.

The lead candidate CD8 ImmunoPET imaging agent is currently in Phase II clinical trials and has been licensed by numerous pharmaceutical and biotech companies for imaging in their immunotherapy clinical trials, primarily in oncology.

CD8 ImmunoPET is a 89Zr-labelled minibody that has been designed to bind to the CD8 receptor on human T cells for quantitative, non-invasive PET imaging of CD8+ T cells.

CD8+ T cells are the main effector cells involved in the immune response against tumour cells induced by immunotherapies and they also play a key role in multiple autoimmune diseases.

As such, quantitative imaging of CD8+ T cells is currently being researched to determine whether it may be used to diagnose the immune status of a patient, to measure the efficacy of immunotherapies and predict patient outcomes.